The announcement was made at a ceremony hosted by the European Council, France, South Africa and WHO in the presence of President Macron, President Ramaphosa, the President of the European Council, Charles Michel and the President of the European Commission, Ursula von der Leyen.
The global mRNA technology transfer hub was established in 2021 to support manufacturers in low-and middle-income countries to produce their own vaccines, ensuring that they have all the necessary operating procedures and know-how to manufacture mRNA vaccines at scale and according to international standards.
CAPE TOWN – At the European Union – African Union summit in Brussels on Friday, World Health Organization WHO Director-General, Dr Tedros Adhanom Ghebreyesus, announced the first six countries that would receive the technology needed to produce mRNA vaccines on the African continent.
Egypt, Kenya, Nigeria, Senegal, South Africa and Tunisia all applied and have been selected as recipients, the global health authority said in a statement.
The announcement was made at a ceremony hosted by the European Council, France, South Africa and WHO in the presence of President Macron, President Ramaphosa, the President of the European Council, Charles Michel and the President of the European Commission Ursula von der Leyen.
The global mRNA technology transfer hub was established in 2021 to support manufacturers in low-and middle-income countries to produce their own vaccines, ensuring that they have all the necessary operating procedures and know-how to manufacture mRNA vaccines at scale and according to international standards.
Primarily set up to address the Covid-19 emergency, the hub has the potential to expand manufacturing capacity for other products as well, putting countries in the driver’s seat when it comes to the kinds of vaccines and other products they need to address their health priorities.
Depending on the infrastructure, workforce, clinical research, and regulatory capacity in place, WHO and partners will work with the beneficiary countries to develop a roadmap and put in place the necessary training and support so that they can start producing vaccines as soon as possible, said WHO.
WHO Director-General Dr Tedros Adhanom Ghebreyesus said: No other event like the Covid-19 pandemic has shown that reliance on a few companies to supply global public goods is limiting and dangerous. In the mid-to-long term, the best way to address health emergencies and reach universal health coverage is to significantly increase the capacity of all regions to manufacture the health products they need, with equitable access as their primary endpoint.
South Africa’s President Cyril Ramaphosa said: This is an initiative that will allow us to make our own vaccines and that, to us, is very important. It means mutual respect, mutual recognition of what we can all bring to the party, investment in our economies, infrastructure investment and, in many ways, giving back to the continent.
President Emmanuel Macron of France said: Improved public health benefits, supporting African health sovereignty and economic development are the principal goals of strengthening local production in Africa. In an interconnected world, we need stronger and new partnerships between countries, development partners and other stakeholders to empower regions and countries to fend for themselves during crises and in peacetime.
President Charles Michel, from the European Counci,l said: We need to create an environment where every scientist, health worker, and government can band together for a common cause. Working together to build new solutions to protect what is most precious – our health and our lives.
To ensure that all countries build the necessary capacity to produce their own vaccines and other health technologies, the WHO has been working to establish a bio-manufacturing workforce training hub that will train people from all interested countries in scientific and clinical research and production capacity. The training hub will be announced in the coming weeks.
In addition, WHO’s current regulatory strengthening activities in low- and middle-income countries will expand through a global benchmarking tool that assesses countries’ ability to ensure the quality, safety and efficacy of health products and provides training where improvements are needed to build regulatory authorities that are agile and fit-for-purpose for the future, the global health authority said on Friday.
IOL
